| Autor: |
Dandu, Himanshu, Kumar, Naveen, Kumar, Neeraj, Malhotra, Hardeep Singh, Prabhu, Vikas, Bharti, Vipin Raj, Gupta, Prashant, Yadav, Geeta, Verma, Veerendra |
| Zdroj: |
Mycopathologia; Aug2024, Vol. 189 Issue 4, p1-10, 10p |
| Abstrakt: |
Background: During the COVID-19 pandemic-associated mucor epidemic, acute antifungal drug shortage necessitated the exploration of other antifungals based on culture sensitivity. Itraconazole is a cheap, safe, and effective antifungal in sensitive cases. Methodology: We enrolled itraconazole-sensitive COVID-19-associated mucormycosis during the mucormycosis pandemic. After the intensive phase course of liposomal amphotericin B, Itraconazole was offered in susceptible cases during the maintenance phase along with standard of care. These patients were clinically and radiologically followed for 6 months. Results: We enrolled 14 patients (Male: Female–11:3) of Rhino-orbito-cerebral mucormycosis (ROCM) which included 12 diabetics. All patients had facial swelling, orbital swelling, visual impairment, and headache. MRI showed involvement of bilateral sinus (10/14), orbital extension (13/14), cavernous sinus (5/14), cerebral part of the internal carotid artery (3/14), and brain infarcts (4/14). All 14 patients showed sensitivity to Itraconazole with 12 having minimum inhibitory concentration (MIC) ≤ 1 μg/ml and 2 having MIC ≤ 2 μg/ml. Follow-up at 6 months showed clinical improvement in the majority (11/14) and radiological improvement in six out of seven scanned patients. Conclusion: Our study shows the potential therapeutic role of oral Itraconazole in ROCM. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink